ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1131 • ACR Convergence 2020

    Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model

    Mithu Maheswaranathan1, Kevin McKenna2, Amy Corneli2, David Pisetsky3, Megan Clowse4 and Amanda Eudy1, 1Duke University, Durham, NC, 2Duke University, Durham, 3Duke University Medical Center, Durham, NC, 4Duke University, Chapel Hill, NC

    Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used.  We…
  • Abstract Number: 1137 • ACR Convergence 2020

    Access to Digital Health in an Urban Rheumatology Population

    Bruce Youm1 and Aruni Jayatilleke2, 1University of the Pacific, Arthur A. Dugoni School of Dentistry, San Jose, CA, 2Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

    Background/Purpose: Advances in treatment of rheumatologic diseases have increased emphasis on physician and patient use of health information technologies (HIT). While studies indicate that e-health…
  • Abstract Number: 1136 • ACR Convergence 2020

    Survey of Medical Cannabis Use in Lupus and Scleroderma

    Wassim Karkache1 and Catherine Ivory2, 1University of Ottawa, Ottawa, ON, Canada, 2University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa, ON, Canada

    Background/Purpose: Despite the lack of research regarding medical cannabis, marijuana and its by-products have gained popularity over the last decades. A 2019 Statistics Canada report…
  • Abstract Number: 1142 • ACR Convergence 2020

    Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

    Rebecca Overbury1, Tracy Frech2, John Bohnsack3, CJ Inman1, Sara Stern1, Karen James1, Erin Treemarcki4 and Aimee Hersh4, 1University of Utah and Primary Children's Hospital, Salt Lake City, UT, 2University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, 3University of Utah and Primary Children's Hospital, Cincinnati, OH, 4University of Utah and Primary Children's Hospital, Salt Lake City

    Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
  • Abstract Number: 1144 • ACR Convergence 2020

    Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic

    Michael George1, Shilpa Venkatachalam2, Shubhasree Banerjee1, Joshua Baker1, Peter Merkel1, David Curtis3, Kelly Gavigan4, Maria (Maio) Danila5, Jeffrey R Curtis6 and William Nowell7, 1University of Pennsylvania, Philadelphia, PA, 2Global Healthy Living Foundation, Upper Nyack, 3Global Healthy Living Foundation, New York City, 4Global Healthy Living Foundation, Upper Nyack, NY, 5University of Alabama at Birmingham (UAB), Birmingham, AL, 6Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Global Healthy Living Foundation, New York City, NY

    Background/Purpose: Patients with autoimmune rheumatic diseases may be particularly concerned about COVID-19. We aimed to assess concerns and associated health behaviors of patients with autoimmune…
  • Abstract Number: 1139 • ACR Convergence 2020

    Primary Non-adherence in Patients with Systemic Lupus Erythematosus

    Ankoor Shah1, Megan Clowse2, Daniel Wojdyla1 and Amanda Eudy1, 1Duke University, Durham, NC, 2Duke University, Chapel Hill, NC

    Background/Purpose: Up to 50% of patients with systemic lupus erythematosus (SLE) are nonadherent to their medications, which increases the risk of renal failure and death…
  • Abstract Number: 1134 • ACR Convergence 2020

    Prevalence of Frailty and Associated Factors in a National Observational Cohort of Rheumatic Diseases

    Katherine Wysham1, Joshua Baker2, Kristin Wipfler3, Sarah Lieber4, Sebastian Sattui4, Patricia Katz5 and Kaleb Michaud6, 1VA Puget Sound/University of Washington, Seattle, WA, 2University of Pennsylvania, Philadelphia, PA, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4Hospital for Special Surgery, New York, NY, 5University of California, San Francisco, Novato, CA, 6University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Frailty is associated with poor health outcomes in the general population, and recent studies have highlighted its importance in rheumatic musculoskeletal diseases (RMDs). Prior…
  • Abstract Number: 1147 • ACR Convergence 2020

    Development of a Digital Toolkit to Improve Quality of Life of Patients with Systemic Lupus Erythematosus: A Pilot Study

    Jerik Leung1, Ashish Shrestha1, Jennifer Ra2, Laura Brennan3, Alfred Kim4 and Elizabeth Baker1, 1Saint Louis University, College for Public Health and Social Justice, St. Louis, 2Washington University School of Medicine, Lake Forest, CA, 3Transtria, St. Louis, 4Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Individuals living with systemic lupus erythematosus (SLE) face a number of challenges in managing their condition. Initial interviews and community forums with SLE patients…
  • Abstract Number: 1150 • ACR Convergence 2020

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis1, Denise Pires Marafon1, Ivan Caiello1, Manuela Pardeo1, Giulia Marucci1, Emanuela Sacco1, Giusi Prencipe1, Fabrizio De Benedetti2 and Claudia Bracaglia1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 2Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role.…
  • Abstract Number: 1151 • ACR Convergence 2020

    Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia

    Michael Zhang1, Corinne Schneider2, Vinh Dang2 and Scott Canna3, 1Children's Hospital UPMC, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, 3University of PIttsburgh, Pittsburgh, PA

    Background/Purpose: Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) epitomize a diverse and deadly group of inflammatory hyperferritinemic syndromes. Early biomarkers distinguishing these syndromes, especially…
  • Abstract Number: 1146 • ACR Convergence 2020

    Pilot Study of an Internet-Based Pain Coping Skills Training Program for Patients with Systemic Lupus Erythematosus

    Kelli Allen1, Tyler Beuchamp2, Rebecca Cleveland3, Kimberlea Grimm1, David Hu1, Katie Huffman1, Frances Keefe4, Julie Norfleet1, Christine Rini5, Andres Santana1, Shruti Saxena Beem6 and Saira Sheikh7, 1University of North Carolina at Chapel Hill, Chapel HIll, NC, 2Medical College of Georgia, Augusta, GA, 3University of North Carolina, Chapel Hill, NC, 4Duke University Medical Center, Durham, NC, 5Northwestern University, Chicago, IL, 6University of North Carolina at Chapel Hill, Chapel Hill, 7University of North Carolina Thurston Arthritis Research Center, Chapel Hill

    Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have increased symptoms of fatigue, chronic pain, depression and anxiety, which are associated with negative impacts on quality…
  • Abstract Number: 1157 • ACR Convergence 2020

    Health and Socioeconomic Outcomes in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed for a Median of Fifteen Years

    Sara Alehashemi1, Megha Garg2, Kim Johnson3, Kelly King4, Chris Zalewski4, Debbie Payne5, Adriana de Jesus6, Joseph Snow7, Wadih Zein5, M. Teresa Magone5, Rachel Bishop8, Carmen Brewer4, Jeff Kim4, Scott Paul9, John Butman10 and Raphaela Goldbach-Mansky11, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, 2NIH/NIAID, Rochester, NY, 3NIH, NIAID, Bethesda, 4NIH, NIDCD, Bethesda, MD, 5NIH/NEI, Bethesda, MD, 6Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, 7NIH, NIMH, Bethesda, MD, 8NIH, NEI, Bethesda, MD, 9NIH, CC/RMD, Bethesda, MD, 10NIH, CC/DRD, Bethesa, MD, 11Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD

    Background/Purpose: Patients (pts) with NOMID have systemic inflammation and organ damage such as sensorineural hearing loss, hydrocephalus, optic nerve atrophy and growth plate defects. IL-1 blocking…
  • Abstract Number: 1154 • ACR Convergence 2020

    Distinct Gene Signature Predicts Strong Clinical Responses to Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis

    Emely Verweyen1, Alex Pickering2, Alexei Grom3 and Grant Schulert4, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Harvard Medical School, Boston, MA, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Canakinumab is a human anti-IL1β blocking agent that effectively neutralizes IL1β mediated signaling and is used to treat diseases such as systemic juvenile idiopathic…
  • Abstract Number: 1149 • ACR Convergence 2020

    Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA)

    Simone Carbogno1, Denise Pires Marafon2, Giulia Marucci2, Emanuela Sacco2, Manuela Pardeo2, Alhanouf Alsaleem3, Sarka Fingerhutova4, Ferhat Demir5, Nastasia Cekada6, Mikhail Kostik7, Christoph Kessel8, Olga Vougiouka9, Alenka Gagro10, Jessica Tibaldi11, Francesca Minoia12, Ilaria Maccora13, Rayfel Schneider14, Pavla Dolezalova15, Betul Sozeri16, Marija Jelusic6, Antonella Insalaco2, Fabrizio De Benedetti17 and Claudia Bracaglia2, 1Pediatric Area, University of Milan, Milan, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 3Division of Pediatric Rheumatology, Department of pediatrics, King Faisal specialist hospital and research center, Riyadh, Saudi Arabia, RiYADH, Saudi Arabia, 4Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, Charles University in Prague, Dlouha 534, Kladno, 27201, Czech Republic, 5University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, 6University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, 7Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, Sto arrivando!, Russia, 8Department of Pediatric Rheumatology and Immunology, University Hospital Muenster, Muenster, Germany, Muenster, Germany, 9Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, Athens, Greece, 10Children's Hospital Zagreb, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, 11UOC Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Italy, 12Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 13Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, 14University of Toronto, The Hospital for Sick Children, Toronto, Canada, 15Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, Prague, Czech Republic, 16University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology Istanbul, Turkey, Istanbul, Turkey, 17Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of Systemic Juvenile Idiopathic Arthritis (sJIA) with a significant mortality. A score that identify sJIA…
  • Abstract Number: 1041 • ACR Convergence 2020

    Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center

    Sanjeev Patil1, Justine Cheng2, Lorraine Provencher3 and Scott Vogelgesang4, 1University of Vermont Medical Center, Essex Junction, VT, 2University of Iowa Hospitals and Clinics, Iowa City, IA, 3Cincinnati Eye Institute, Cincinnati, OH, 4University of Iowa Hospitals and Clinics, Iowa City, IA

    Background/Purpose: Non-Infectious Ocular inflammatory disease (OID) is a group of immune-mediated diseases involving the ocular surface, uveal tract, retina, optic nerve, and peri-orbital tissue. Patients…
  • « Previous Page
  • 1
  • …
  • 701
  • 702
  • 703
  • 704
  • 705
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology